Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of RAS(ON) Inhibitors in Gastrointestinal Solid Tumors
NCT06445062Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- May 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of daraxonrasib and zoldonrasib in colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and gastrointestinal cancer (7 arms), sponsored by Revolution Medicines. Primary endpoints: Adverse Events up to 3 years, Dose Limiting Toxicities at 28 days and 1 more. Started May 2024; status: recruiting.
02
Drugs
daraxonrasibzoldonrasib
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)gastrointestinal cancer
Beyond the preview
Go deeper on NCT06445062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445062.